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Abstract
Problem: Human β- defensins (HBDs) are antimicrobial peptides that participate in 
the soluble innate immune mechanisms against infection. Herein, we determined 
whether HBD- 1 was present in amniotic fluid during normal pregnancy and whether 
its concentrations change with intra- amniotic inflammation and/or infection.
Method of Study:	Amniotic	 fluid	was	 collected	 from	219	women	 in	 the	 following	
groups: (a) midtrimester who delivered at term (n = 35); (b) term with (n = 33) or with-
out (n = 17) labor; (c) preterm labor with intact membranes who delivered at term 
(n = 29) or who delivered preterm with (n = 19) and without (n = 29) intra- amniotic 
inflammation and infection or with intra- amniotic inflammation but without infection 
(n = 21); and (d) preterm prelabor rupture of membranes (pPROM) with (n = 19) and 
without	 (n	=	17)	 intra-	amniotic	 inflammation/infection.	Amniotic	 fluid	HBD-	1	 con-
centrations	were	determined	using	a	sensitive	and	specific	ELISA	kit.
Results: (a) HBD- 1 was detectable in all amniotic fluid samples; (b) amniotic fluid 
concentrations of HBD- 1 were changed with gestational age (midtrimester vs term 
no labor), being higher in midtrimester; (c) amniotic fluid concentrations of HBD- 1 
were similar between women with and without spontaneous labor at term; (d) among 
patients with spontaneous preterm labor, amniotic fluid concentrations of HBD- 1 in 
women with intra- amniotic inflammation/infection and in those with intra- amniotic 
inflammation without infection were greater than in women without intra- amniotic 
inflammation or infection who delivered preterm or at term; and (e) the presence of 
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1  | INTRODUC TION
The amniotic fluid and placenta have antimicrobial properties 
and function as an immunological barrier to the growing fetus.1-9 
Specifically, the amniotic fluid contains soluble components such as 
electrolytes, carbohydrates, lipids, and peptides which can act as a 
defense against pathogens invading the amniotic cavity.10-30 The 
amniotic fluid also includes cellular components31-45 that have been 
recently characterized using immunophenotyping.46 It is now clear 
that amniotic fluid contains both innate and adaptive immune cells 
such as monocytes/macrophages, neutrophils, innate lymphoid cells, 
B cells, natural killer cells, and T cells.46 Most of these immune cells 
are more abundant in women with intra- amniotic infection and/or in-
flammation.46	Among	innate	immune	cells,	neutrophils	are	considered	
a marker of intra- amniotic inflammation as their number is increased 
in women with intra- amniotic infection.47,48 While amniotic fluid neu-
trophils are mostly of fetal origin in preterm gestations, they can also 
be of maternal origin at term.49 Regardless of their origin, amniotic 
fluid neutrophils participate in the host defense mechanisms against 
intra- amniotic infection by performing phagocytosis,50 forming neu-
trophil extracellular traps or NETs,51 and releasing inflammatory me-
diators48,52-78 including an array of antimicrobial peptides.18,79-84
Antimicrobial	 peptides	 represent	 soluble	 mediators	 of	 the	
innate immune system, which provide protection against patho-
gens.85-91 Several families of antimicrobial peptides have been 
described in mammals, such as cathelicidins and defensins.92,93 
The latter are small cationic peptides synthesized by neutrophils, 
Paneth cells, and epithelial cells85,94-99 and are regulated primar-
ily by microbial signals and cytokines, and in some cases by neu-
roendocrine signals in a tissue- specific manner.90,95,100 Defensins 
can be of different types based on their function and location 
of expression in the human body.90 Two main types of defen-
sins have been identified in humans: α- and β- defensins.101,102 
Alpha	 defensins	 are	 seen	 in	 azurophilic	 granules	 in	 neutro-
phils85,94,103,104 and have also been identified in the Paneth cells 
of intestinal crypts.95,98,105,106 These mediators have six subtypes 
referred to as human neutrophil peptide (HNP)- 1 to HNP- 4 and 
human defensin- 5 and human defensin- 6.90 Increased concentra-
tions of HNP- 1 in amniotic fluid have been associated with in-
trauterine infection and acute histologic chorioamnionitis.107,108
Human β- defensins (HBD) are expressed in the epithelial cells of 
mucosal surfaces.86,99,109 HBD- 1, HBD- 2, and HBD- 3 proteins have 
all been localized in the reproductive tissues including the amnion 
epithelium, chorion trophoblast, decidua, and placental syncytiotro-
phoblast.110 HBD- 2 has also been detected in amniotic fluid, and its 
concentration is increased in women with intra- amniotic inflamma-
tion/infection who underwent spontaneous preterm labor with intact 
membranes and in those with preterm prelabor rupture of membranes 
(pPROM).84 However, whether HBD- 1 can be detected in amniotic 
fluid during normal pregnancy and its complications is unknown.
The aims of this study were to (a) detect HBD- 1 in amniotic fluid 
of women in midgestation and at term with or without labor; (b) inves-
tigate whether HBD- 1 was increased in amniotic fluid of women who 
underwent spontaneous preterm labor with intact membranes and 
intra- amniotic inflammation and/or infection; and (c) determine whether 
HBD- 1 concentrations were different between women who underwent 
pPROM with or without intra- amniotic inflammation/infection.
2  | MATERIAL S AND METHODS
2.1 | Study design and population
This was a cross- sectional study that was conducted by evaluating 
our clinical database and bank of biological samples. The collection 
of samples was approved by the Institutional Review Boards of the 
Detroit	Medical	Center	(Detroit,	MI,	USA),	Wayne	State	University,	
and the Perinatology Research Branch, an intramural program of the 
Eunice Kennedy Shriver National Institute of Child Health and Human 
Development, National Institutes of Health, US Department of 
Health	and	Human	Services.	All	women	provided	written	informed	
consent prior to collecting amniotic fluid.
We utilized 219 amniotic fluid samples which were divided into 4 
groups. Group 1 comprised amniotic fluid from women who underwent 
intra- amniotic inflammation and infection in patients with pPROM did not change 
amniotic fluid concentrations of HBD- 1.
Conclusion: HBD- 1 is a physiological constituent of amniotic fluid that is increased in 
midtrimester during normal pregnancy and in the presence of culturable microorgan-
isms in the amniotic cavity. These findings provide insight into the soluble host de-
fense mechanisms against intra- amniotic infection.
K E Y W O R D S
acute chorioamnionitis, cytokines, danger signals, fetal immunity, funisitis, innate immunity, 
microbial invasion of the amniotic cavity, neutrophils, preterm PROM, sterile intra-amniotic 
inflammation
     |  3 of 13VARREY Et Al.
amniocentesis during midtrimester (14- 18 weeks) for genetic indica-
tions and delivered a normal full- term neonate (n = 35; Table 1). Group 
2 included amniotic fluid samples from women with normal pregnan-
cies who underwent amniocentesis at term (>37 weeks) with (n = 33) 
and without (n = 17) spontaneous labor (Table 1). Group 3 included 
women who underwent spontaneous preterm labor with intact mem-
branes and were further classified into women who underwent (a) 
spontaneous preterm labor who proceeded to have a term delivery 
with a negative amniotic fluid culture and interleukin (IL)- 6 <2.6 ng/mL 
(n = 29), (b) spontaneous preterm labor without intra- amniotic inflam-
mation or infection (n = 29; see diagnostic criteria below), (c) sponta-
neous preterm labor with intra- amniotic inflammation and a negative 
amniotic fluid culture (n = 21), and (d) spontaneous preterm labor with 
intra- amniotic inflammation and infection proven by a positive amni-
otic fluid culture (n = 19; Table 2). Lastly, Group 4 consisted of amniotic 
fluid samples from women who underwent pPROM with (n = 19) and 
without (n = 17) intra- amniotic inflammation and infection (Table 3).
The inclusion criteria for uncomplicated pregnancies were as 
follows: (a) no medical, obstetrical, or surgical complications, (b) ab-
sence	of	microbial	invasion	of	the	amniotic	cavity	(MIAC;	see	diag-
nostic criteria below), (c) amniotic fluid IL- 6 concentrations <2.6 ng/
mL, (d) intact membranes, and (e) delivery of a term neonate with 
birthweight appropriate for gestational age.
2.2 | Clinical definitions
Spontaneous preterm labor was defined as regular uterine contrac-
tions (at least two contractions every 10 minutes) associated with 
cervical	 changes.	 MIAC	 was	 defined	 by	 a	 positive	 amniotic	 fluid	
culture for microorganisms.111-123 Intra- amniotic inflammation was 
defined	as	an	amniotic	fluid	IL-	6	concentration	≥2.6	ng/mL.118 Intra- 
amniotic	infection	was	defined	as	the	presence	of	MIAC	with	intra-	
amniotic inflammation.77,118,120,121,124-138 Preterm prelabor rupture of 
membranes (pPROM) had to occur prior to the onset of labor before 
37 weeks and was diagnosed by vaginal pooling of amniotic fluid, am-
niotic fluid ferning patterns, and a positive nitrazine test.139-142
2.3 | Sample collection
Amniotic	fluid	was	retrieved	by	transabdominal	amniocentesis,	under	
antiseptic conditions and monitored by ultrasound. Transabdominal 
amniocentesis in patients from groups 2, 3, and 4 was performed for 
the detection of intra- amniotic inflammation and/or infection and 
fetal lung maturity tests. The remaining amniotic fluid that was not 
required for clinical purposes was centrifuged at 4°C and 1300× g for 
10 minutes for the removal of cellular and particulate matter, and the 
supernatants	were	stored	at	−80°C.	A	portion	of	this	amniotic	fluid	
was also transported to the laboratory for culture of aerobic/anaero-
bic bacteria and genital mycoplasmas. The clinical tests also included 
the determination of amniotic fluid white blood cell (WBC) count,47 
glucose concentration,143 Gram stain,144 and IL- 6 concentration.118
2.4 | Determination of IL- 6 in amniotic fluid
Amniotic	fluid	concentrations	of	IL-	6	were	determined	using	a	sensi-
tive and specific enzyme immunoassay obtained from R&D systems 
(Minneapolis,	MN,	USA).	The	IL-	6	concentrations	were	determined	
by interpolation from the standard curves. The inter- and intra- assay 
coefficients of variation for IL- 6 were 8.7% and 4.6%, respectively. 
The detection limit of the IL- 6 assay was 0.09 pg/mL. The IL- 6 con-
centrations in amniotic fluid were determined for clinical purposes.
2.5 | Detection of HBD- 1 by ELISA
HBD- 1 was detected in amniotic fluid using the Total Beta Defensin 
1	 ELISA	 Kit	 from	 Aviscera	 Bioscience	 (Cat#SK00858-	06,	 Santa	
Clara,	CA,	USA).	This	ELISA	kit	was	validated	in	our	laboratory	prior	
to	execution	of	the	study.	Amniotic	fluid	concentrations	of	HBD-	1	
TABLE  1 Clinical and demographic characteristics of women who underwent an amniocentesis during midtrimester or at term pregnancy
Normal pregnancy 
Midtrimester (n = 35) Term no labor (n = 17) Term in labor (n = 33) P- value
Maternal age (y)a 37 (35- 39) 24 (21- 32) 23 (20- 29) <0.001
Nulliparousb 17.1% (6/35) 23.5% (4/17) 42.4% (14/33) 0.058
Raceb
African	American 85.7% (30/35) 0 0 <0.001
Caucasian 5.7% (2/35) 0 0
Hispanic 0 100% (17/17) 100% (33/33)
Other 8.6 (3/35) 0 0
Gestational age at amniocentesis (wk)a 16 (16- 17) 39 (38.5- 40) 39 (38- 40) <0.001
Gestational age at delivery (wk)a 39 (38- 40) 39 (38.5- 40) 39 (38- 40) 0.8
Birthweight (g)a 3344 (3176- 3621) 3260 (3130- 3790) 3280 (3085- 3715) 0.7
Amniotic	fluid	IL-	6	(ng/mL)a 0.68 (0.34- 1.06) 0.41 (0.22- 0.85) 1.04 (0.5- 1.37) 0.04
Data are given as median (interquartile range) and percentage (n/N).
aKruskal- Wallis/Mann- Whitney U test.
bFisher’s exact test.
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were obtained by interpolation from the standard curve. The inter- 
and intra- assay coefficients of variation were 14.56% and 11.47%, 
respectively. The sensitivity of the assay was 8.96 pg/mL.
2.6 | Statistical analysis
Statistical analysis was performed using the SPSS v19 software 
(SPSS	 Inc.,	 IBM	Corporation,	Armonk,	NY,	USA).	Normality	 of	 the	
data was tested using the Shapiro- Wilk test. Nonparametric testing 
was applied for comparisons, and adjustments for multiple compari-
sons were performed when indicated. Comparisons of the propor-
tions	were	made	using	Fisher’s	exact	tests.	A	P- value of <0.05 was 
used to determine statistical significance.
3  | RESULTS
The demographic and clinical characteristics of the study populations 
are displayed in Tables 1–3. Nulliparity rate was similar among the 
study groups. The maternal age and race were significantly different 
between women in the midtrimester group and those at term with 
or without labor (Table 1), but did not differ among the preterm labor 
or pPROM groups (Tables 2 and 3). The neonatal birthweights were 
significantly different among the preterm labor groups (Table 2) and 
pPROM	groups	(Table	3).	Amniotic	fluid	IL-	6	concentrations	were	el-
evated in women with spontaneous labor at term compared to those 
who delivered at term without labor (Table 1) and, as expected, were 
increased in women with intra- amniotic inflammation and/or infec-
tion compared to those without this clinical condition (Tables 2 and 
3). HBD- 1 was detected in all 219 amniotic fluid samples.
3.1 | Amniotic fluid HBD- 1 concentration 
in normal pregnancy
The concentration of HBD- 1 in amniotic fluid was higher in the 
midtrimester group than in the term no labor group [midtrimester: 
median 13.73 ng/mL (IQR 6.87- 20.44 ng/mL) vs term no labor: me-
dian 9.07 ng/mL (IQR 6.93- 12.15 ng/mL), P = 0.03] (Figure 1).
The concentration of HBD- 1 in amniotic fluid was similar be-
tween the term no labor and term labor groups (term no labor: 
median 9.07 ng/mL [IQR 6.93- 12.15 ng/mL] vs term labor: median 
6.44 ng/mL [IQR 3.59- 11.45 ng/mL], P = 0.1; Figure 2).
3.2 | Amniotic fluid HBD- 1 concentration in women 
with spontaneous preterm labor
Among	 women	 who	 presented	 with	 spontaneous	 preterm	 labor,	 the	
median amniotic fluid concentration of HBD- 1 was higher in women 
TABLE  2 Clinical and demographic characteristics of women who underwent spontaneous preterm labor
Preterm labor 
delivered at term 
(n = 29)
Preterm labor without 
intra- amniotic 
inflammation or 
infection (n = 29)
Preterm labor with 
intra- amniotic 
 inflammation but without 
infection (n = 21)
Preterm labor with 
intra- amniotic inflammation 
and infection (n = 19) P- value
Maternal age (y)a 23 (20- 30) 25 (22- 30) 22 (20- 26) 25 (20- 29) 0.6
Nulliparousb 24.1% (7/29) 34.5% (10/29) 42.9% (9/21) 63.2% (12/19) 0.06
Raceb
African	American 86.2 (25/29) 85.1% (23/27)d 85% (17/20)c 100% (19/19) 0.4
Caucasian 10.3% (3/29) 14.8% (4/27)d 10% (2/20)c 0
Hispanic 3.4% (1/29) 0 5% (1/20)c 0
Gestational age at 
amniocentesis (wk)a
29.3 (27.6- 31.2) 28.7 (26.6- 32) 25 (22- 28.1) 24.6 (20.35- 27) <0.001
Gestational age at 
delivery (wk)a
38 (37- 40) 33 (31- 36) 28 (22.3- 31) 25 (20.4- 29.25) <0.001
Birthweight (grams)a 2930 (2600- 3150) 1960 (1390- 2320) 830 (480- 1300) 610 (430- 1177.5) <0.001
Amniotic	fluid	IL-	6	
(ng/mL)a
0.55 (0.23- 0.76) 0.92 (0.36- 1.32) 28.43 (9.54- 60.7) 172.4 (87.74- 350.91) <0.001
Amniotic	fluid	
glucose (mg/dL)a
37 (28.5- 51.5)e 32 (27- 36.5)f 27 (21.5- 29)e 16 (10- 28) <0.001
Amniotic	fluid	white	
blood cells (/mm3)a
1 (0- 4.5) 1 (0- 4) 9 (2- 119.3)c 486 (7- 1152) <0.001
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with intra- amniotic inflammation and infection than in those who deliv-
ered at term (preterm labor with intra- amniotic inflammation and infec-
tion who delivered preterm: median 24.36 ng/mL [IQR 17.34- 38.91 ng/
mL] vs preterm labor who delivered at term: median 10.87 ng/mL [IQR 
8.82- 13.94 ng/mL], P < 0.001; Figure 3). The median amniotic fluid con-
centration of HBD- 1 was also greater in women with intra- amniotic 
inflammation and infection than in those without intra- amniotic inflam-
mation or infection who delivered preterm (preterm labor with intra- 
amniotic inflammation and infection who delivered preterm: median 
24.36 ng/mL [IQR 17.34- 38.91 ng/mL] vs preterm labor without intra- 
amniotic inflammation or infection who delivered preterm: median 
12.2 ng/mL [IQR 8.02- 18.58 ng/mL], P = 0.006; Figure 3). Patients who 
underwent spontaneous preterm labor with intra- amniotic inflammation 
but without detected microorganisms had a higher median amniotic fluid 
concentration of HBD- 1 than those with preterm labor who delivered at 
term (preterm labor with intra- amniotic inflammation but without infec-
tion who delivered preterm: median 18.31 ng/mL [IQR 12.17- 32.15 ng/
mL] vs preterm labor who delivered at term: median 10.87 ng/mL [IQR 
8.82- 13.94 ng/mL], P = 0.003; Figure 3). Patients who underwent spon-
taneous preterm labor with intra- amniotic inflammation but without in-
fection also had a higher median amniotic fluid concentration of HBD- 1 
than those with preterm labor without intra- amniotic inflammation or in-
fection who delivered preterm (preterm labor with intra- amniotic inflam-
mation but without infection who delivered preterm: median 18.31 ng/
mL [IQR 12.17- 32.15 ng/mL] vs preterm labor without intra- amniotic in-
flammation or infection who delivered preterm: median 12.2 ng/mL [IQR 
8.02- 18.58 ng/mL], P	=	0.02;	 Figure	3).	 Yet,	 there	were	 no	 differences	
between women with preterm labor and intra- amniotic inflammation 
and infection and those with intra- amniotic inflammation but without 
infection (preterm labor with intra- amniotic inflammation and infection 
who delivered preterm: median 24.36 ng/mL [IQR 17.34- 38.91 ng/mL] 
vs preterm labor with intra- amniotic inflammation but without infection 
who delivered preterm: median 18.31 ng/mL [IQR 12.17- 32.15 ng/mL], 
P = 0.9; Figure 3). There were no differences between women who un-
derwent spontaneous preterm labor without intra- amniotic inflamma-
tion or infection who delivered preterm and those who delivered at term 
(preterm labor without intra- amniotic inflammation or infection who de-
livered preterm: median 12.2 ng/mL [IQR 8.02- 18.58 ng/mL] vs preterm 
labor who delivered at term: median 10.87 ng/mL [IQR 8.82- 13.94 ng/
mL], P	=	0.9;	 Figure	3).	 A	 linear	 regression	model	 was	 fit	 with	 HBD-1	
amniotic fluid concentration as the dependent variable and gestational 
age (continuous) and spontaneous preterm labor groups as independent 
variables. This analysis showed that HBD-1 concentration was not signifi-
cantly associated with gestational age.
3.3 | Amniotic fluid HBD- 1 concentration in 
women with preterm prelabor rupture of membranes 
(pPROM)
Patients with pPROM had similar median amniotic fluid concentrations 
of HBD- 1, irrespective of their intra- amniotic inflammation/infection 
status (pPROM without intra- amniotic inflammation or infection: me-
dian 12.4 [IQR 9.46- 14.77] vs pPROM with intra- amniotic inflamma-
tion and infection: median 15.47 [IQR 8.68- 19.51], P = 0.2; Figure 4).
4  | DISCUSSION
4.1 | The principal findings of this study were as 
follows
(a) HBD- 1 is a physiological constituent of amniotic fluid; (b) amniotic 
fluid concentrations of HBD- 1 changed with gestational age (midtri-
mester vs term no labor), being higher in midtrimester; (c) amniotic 
fluid concentrations of HBD- 1 were similar between women with and 
TABLE  3 Clinical and demographic characteristics of women with preterm prelabor rupture of membranes (pPROM)
pPROM without intra- amniotic 
inflammation or infection (n = 17)
pPROM with intra- amniotic 
 inflammation and infection (n = 19) P- value
Maternal age (y)a 23 (20.5- 31.5) 29 (21- 32) 0.6
Nulliparousb 35.3% (6/17) 31.6% (6/19) 1
Raceb
African	American 94.1% (16/17) 83.3% (15/18)c 0.6
Caucasian 5.9% (1/17) 16.7% (3/18)c
Gestational age at amniocentesis (wk)a 30.6 (26.8- 32.75) 28.3 (24.4- 30.5) 0.07
Gestational age at delivery (wk)a 34 (31.7- 36) 29 (24- 31) <0.001
Birthweight (grams)a 2200 (1807- 2444) 1330 (660- 1710) <0.001
Amniotic	fluid	IL-	6	(ng/mL)a 0.64 (0.25- 1) 64.3 (20.08- 172.8) <0.001
Amniotic	fluid	glucose	(mg/dL)a 28 (24.25- 34.5)d 18 (16- 22) 0.001
Amniotic	fluid	white	blood	cells	(/mm3)a 4 (0- 19) 411 (20- 912) <0.001
Data are given as median (interquartile range) and percentage (n/N).
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without spontaneous labor at term; (d) among patients with spontane-
ous preterm labor, amniotic fluid concentrations of HBD- 1 were greater 
in women with intra- amniotic inflammation and infection than in those 
without intra- amniotic inflammation or infection who delivered preterm 
or at term; (e) amniotic fluid concentrations of HBD- 1 were also higher 
in women with intra- amniotic inflammation but without infection than 
in those without intra- amniotic inflammation or infection who delivered 
preterm or at term; and (f) the presence of intra- amniotic inflammation 
and infection in patients with pPROM did not change amniotic fluid 
concentrations of HBD- 1.
4.2 | HBD- 1 is present in amniotic fluid and its 
concentration changes with gestational age
HBD- 1 was present in amniotic fluid of women with normal preg-
nancy. Consistently, previous studies have shown that other human 
defensins (HBD- 2 and HBD- 3) are present in the second trimester 
amniotic fluid.84,145 Given that fetal tissues including the lungs, pla-
centa, and chorioamniotic membranes, as well as the decidua express 
human defensins,9, 110,146-150 it is likely that both fetal and maternal 
tissues serve as a source for these natural antimicrobial peptides.
The amniotic fluid concentration of HBD- 1 was elevated in 
midtrimester compared to women who delivered at term without 
labor and in those who delivered at term with labor (comparison 
not shown), suggesting that this antimicrobial peptide is more re-
quired in the second trimester than at term pregnancy. This is 
in line with the evidence showing that in midtrimester, most of 
the innate immune cells that participate in host defense mech-
anisms against infection (e.g, neutrophils) are low in number.46 
Therefore, amniotic fluid HBD- 1 may serve as an innate soluble 
component that protects the fetus against invading pathogens 
during	 midtrimester	 when	 neutrophils	 are	 rare.	 As	 gestation	
progresses toward term, the number of neutrophils in amniotic 
fluid increases until these immune cells become the dominant 
leukocyte subset46 and may take over the host defense mecha-
nisms in the amniotic cavity through performing phagocytosis50 
and NET formation,51 as well as releasing other antimicrobial 
peptides.18,79-84
These data indicate that HBD- 1 is a physiological component of 
amniotic fluid during normal pregnancy and that it may be implicated 
in the soluble innate immune mechanisms which occur in the amni-
otic cavity early in gestation.
F IGURE  1 Amniotic	fluid	concentrations	of	human	β- defensin- 1 
(HBD-	1)	in	normal	pregnancy.	Amniotic	fluid	concentrations	of	
HBD-1 in midtrimester and at term without labor. Medians and 
interquartile ranges are shown in red 
F IGURE  2 Amniotic	fluid	concentrations	of	human	β- defensin- 1 
(HBD-	1)	at	term	pregnancy.	Amniotic	fluid	concentrations	of	HBD-1	
in women with and without spontaneous labor at term. Medians 
and interquartile ranges are shown in red
F IGURE  3 Amniotic	fluid	concentrations	of	human	β- defensin- 1 
(HBD- 1) in women with spontaneous preterm labor and intact 
membranes.	Amniotic	fluid	concentrations	of	HBD-1	in	women	
who underwent spontaneous preterm labor and delivered at term 
or preterm with and without intra-amniotic inflammation and/
or infection. Medians and interquartile ranges are shown in red. 
 P- values were adjusted for multiple comparisons
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4.3 | Amniotic fluid HBD- 1 concentrations do not 
differ between women with and without spontaneous 
labor at term
The amniotic fluid concentration of HBD- 1 was similar between women 
with and without spontaneous labor at term. Labor is considered a 
state of physiologic inflammation151-167 as intra- amniotic infection is 
absent in most women who deliver at term.117 Therefore, spontaneous 
labor at term is a sterile inflammatory process and may not need to 
be associated with an increase in the concentration of HBD- 1. This is 
supported by a previous report showing that the expression of HBD- 1 
is unchanged in the placenta and chorioamniotic membranes by the 
process of labor at term.110 These data show that amniotic fluid HBD- 1 
is unchanged by the physiological process of labor at term.
4.4 | Amniotic fluid HBD- 1 concentration is 
increased in women with spontaneous preterm 
labor and intra- amniotic inflammation and/
or infection
Women with spontaneous preterm labor and intra- amniotic in-
flammation	 and	 infection	 (amniotic	 fluid	 IL-	6	 ≥2.6	ng/mL	 and	 a	
positive microbial culture) had higher amniotic fluid concentra-
tions of HBD- 1 than those without intra- amniotic inflammation or 
infection (amniotic fluid IL- 6 <2.6 ng/mL and a negative microbial 
culture) and those who delivered at term. These findings are con-
sistent with a previous report demonstrating that amniotic fluid 
concentration	of	HBD-	2	is	increased	in	women	with	MIAC	and	in-
flammation.84 The data presented herein are also consistent with 
in vitro studies indicating that Candida albicans can increase the 
release of HBD- 1 by the chorioamniotic membranes.168 The intra- 
amniotic inflammatory process associated with elevated amniotic 
fluid concentrations of HBD- 1 may be mediated by toll- like recep-
tors (TLRs) such as TLR- 4 and TLR- 2, which had been implicated 
in the mechanisms that lead to secretion of defensins by epithe-
lial cells.169 Our data, along with previous studies demonstrating 
that	MIAC	results	in	an	increased	concentration	of	lactoferrin,81,82 
lysozyme,19,21 and bacterial/permeability- increasing protein20 
in amniotic fluid and other compartments,107,170-172 suggest that 
antimicrobial peptides participate in the soluble host defense 
mechanisms against intra- amniotic infection173,174 in women with 
spontaneous preterm labor and birth.
Women with spontaneous preterm labor with intra- amniotic 
inflammation	but	without	 infection	 (amniotic	 fluid	 IL-	6	≥2.6	ng/mL	
but a negative microbial culture) had higher amniotic fluid concen-
trations of HBD- 1 than those without intra- amniotic inflammation 
or infection (amniotic fluid IL- 6 <2.6 ng/mL and a negative micro-
bial culture) and those who delivered at term. Given that molecu-
lar microbiological detection of nonculturable microbes was not 
attainable in this study, we cannot discard the possibility that this 
intra- amniotic inflammatory process is sterile in nature. In the case 
that nonculturable microbes are present in the amniotic cavity, the 
resulting intra- amniotic inflammatory response seems to be milder 
than	in	cases	with	culturable	microorganisms,	suggesting	that	MIAC	
potentiates the host response in the amniotic cavity.
In patients with preterm labor, intra- amniotic inflammation can 
also occur in the absence of microbes detected by cultivation and 
molecular microbiological techniques (i.e, sterile intra- amniotic in-
flammation).126,128 We and others have proposed that this sterile in-
flammatory process can be induced by danger signals derived by the 
fetal tissues.175-179 The importance of sterile intra-amniotic inflam-
mation is underscored by the observation that women with such a 
clinical condition have a similar rate of preterm birth and adverse neo-
natal outcomes as those with proven intra- amniotic infection.128 In 
addition, both sterile intra- amniotic inflammation and intra- amniotic 
infection are associated with acute histologic chorioamnionitis and 
funisitis (i.e, acute histologic lesions of the placenta)128 and high 
concentrations of inflammatory cytokines in the amniotic cavity.76 
In line with these findings, our data showed that both women with 
intra- amniotic inflammation/infection and those with intra- amniotic 
inflammation but without infection have high amniotic fluid con-
centrations of HBD- 1. Collectively, these data suggest that HBD- 1 
participates in the host response against nonculturable microbes or 
danger signals in the amniotic cavity.
4.5 | Amniotic fluid HBD- 1 concentration in 
women with preterm prelabor rupture of membranes 
(pPROM) is unchanged by the presence of intra- 
amniotic inflammation and infection
Women with pPROM and intra- amniotic inflammation and infection 
(amniotic	fluid	IL-	6	≥2.6	ng/mL	and	a	positive	microbial	culture)	had	
similar amniotic fluid concentrations of HBD- 1 compared to those 
without intra- amniotic inflammation or infection (amniotic fluid IL- 6 
<2.6 ng/mL but a negative microbial culture). Our previous report 
F IGURE  4 Amniotic	fluid	concentrations	of	human	β- defensin- 1 
(HBD- 1) in preterm prelabor rupture of membranes (pPROM). 
Amniotic	fluid	concentrations	of	HBD-1	in	women	who	underwent	
pPROM with and without intra-amniotic inflammation/ infection. 
Medians and interquartile ranges are shown in red 
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showed that amniotic fluid concentrations of HBD- 2 are higher in 
patients	 with	 pPROM	 and	 MIAC	 than	 in	 those	 without	 MIAC.84 
These findings are explained by evidence indicating that HBD- 1 and 
HBD- 2 show differential expression in inflammatory diseases (e.g, 
periodontitis180) and in human peripheral blood cells stimulated with 
microbial products.181	 Alternatively,	 patients	with	 pPROM	 usually	
received antibiotic treatment,182,183 which could directly reduce the 
release of antimicrobial peptides and neutrophil- mediated antimi-
crobial activity, in addition to decreasing the microbial burden.184,185 
Further research is required to investigate whether antibiotics given 
to women with pPROM can directly inhibit the secretion of HBD- 1 
in the presence of bacteria associated with this clinical condition.
5  | CONCLUSIONS
The findings described herein indicate that HBD- 1 is a physiological 
constituent of amniotic fluid that is increased in midtrimester dur-
ing normal pregnancy as part of the soluble innate immune response 
early	in	gestation.	Amniotic	fluid	HBD-	1	concentrations	are	increased	
in the presence of culturable microorganisms in the amniotic cav-
ity, which may participate in the soluble host defense mechanisms 
against intra- amniotic infection or other inflammatory stimuli (e.g, 
danger signals or nonculturable microorganisms). Further studies 
may investigate the mechanisms whereby HBD- 1 is released into the 
amniotic cavity, its antimicrobial properties against microbes associ-
ated with intra- amniotic infection, and whether danger signals could 
induce its release in the setting of sterile intra- amniotic inflammation.
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